Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
I am a molecular pharmacologist who works at the University of Adelaide, Australia. I have a broad interest in the understanding of how surface receptors can modulate neuronal function and survival, as well as interests in natural product pharmacology and toxicology as well as drug design. I am also interested in evolutionary biology, science communication (committee member of SA Science Communicators). I write for the Conversation on the toxicological impacts of everyday items. I am also an avid amateur astronomer. My astronomy blog is astroblog.
I did postdoctoral work in the Institute of Pharmacology at the Free University of Berlin in 1991-1994, returning to Australia in 1994. I have collaborated with Professor John Carver, Dr. Scot Smid and Professor Colin Barrow on using natural products to attack the neurodegeneration process in Alzheimer’s Disease. I am currently the convenor of the Toxicology Special Interest Group of the Australasian Society for Pharmacology and Toxicology. I am also collaborating with Professor Roger Byard on the forensic implications of herbal medicines. I have held NH&MRC funding and ARC funding.
- My Research
- Grants and Funding
- Professional Activities
The main thrust of my research has been the role of signal transduction in neuronal function. In recent years this has extended into the area of neuroprotection and neurotoxicity. This has been followed on three fronts; the role of amyloid peptides in neurotoxicity, and how this may be combated with natural products. This work is undertaken with Professor John Carver and Dr. Scott Smid. We have found potent products that can prevent and disrupt amyloid formation. This has profound implications not only for the therapy of Alzhemiers disease, but for a wide range disease that involve of protein misfolding, from systemic amyloidosis to HIV infection.
As well, I have formed collaboration with Professor Colin Barrow (with whom I have collaborated on imidazloine receptor research) in an ARC linkage grant (LP100100069) to look at the role of defensins in ameliorating amyloid damage. My work in this area has been recognised by my being elected to the co-convernor role of the Healthy Ageing Research Cluster, which promoted Ageing research in South Australia (and through which I represented University of Adelaide Researchers at the State government Aging Research round table), until 2010.
As a further logical development of the natural product theme my work has branched out into neurotoxicology with work with Professor Roger Byard and Professor Michael Bunce (Curtin University WA) looking at the toxicity of herbal medicines. (NHMRC Grant APP1061329) As result of this work we have a collaboration with the TGA and have been able to advise them of potentially dangerous herbal medicines.
More recently I have developed collaboration on cynaobacterial toxins with Dr. Andrew Humpage at the Australian Water Quality Centre, SA water
My work in this area was been recognised by my being elected to the co-convernor role of the Healthy Ageing Research Cluster, which promotes Ageing research in South Australia (and through which I represented University of Adelaide Researchers at the State government Aging Reserach round table). More recently I become convenor, then chair, of the Toxoicology Special Interest Group in the Australasian Society of Clinical and Experimental Pharmacologists andToxicologists (ASCEPT), the peak professional body for pharmacologists in Australia. I was recently elected to the ASCEPT Board.
As well, I have had a very productive collaboration with Professor John Bowie investigating defensive neuroptides from frog secretions. These have the potential to be developed into new drugs for pain relief or brain injury.
This focus on neuroprotection developed from my work on imidazoline receptors with Professor John Piletz. There has been some remarkable developments in the field of imidazoline receptor research, some of which I have been privileged to be a part of. My collaborator, Dr. John Piletz, reported the first clone of the I1-receptor and highly selective I1-ligands were shown to produce hypotension in a2-adrenoceptor knock out mice, significantly strengthening a role for these receptors in blood pressure control. Since then, using cells transfected with the cloned imidazoline receptor, we have been able to show that these receptors have significant effects on neuronal growth, survival and neurite formation, as well as being involved in re-organising the neuronal cytoskeleton. For the first time, it appears we have an insight into how these receptors affect neuromodulation and neuroprotection. Furthermore, a wider role in disease states is apparent from results suggesting that imidazoline receptors are involved in mood disorders and modulation of pain perception.
These results built on important results we found in intact animals. In collaboration with Dr Emilio Badoer of the Department of Medical Laboratory Science, and Colin Barrow of the University of Melbourne, I had demonstrated that an endogenous imidazoline ligand, harmane, produces hypotension when micro-injected into the brainstem. This was the first time a candidate endogenous ligand had been shown to modulate blood pressure and represents a significant advance in our knowledge. We have also produced a series of novel compounds that have significant affinity and selectivity for I1-receptors, and are currently testing them functionally. We are currently investigating patenting these compounds. We have also found that I1-receptor ligands, including one of our lead b-carbolines, activate tyrosine kinase, consistent with the structure of the recently described clone. These results are also consistent with the above discoveries of the cloned receptors effects on neuronal growth and survival. Dr. John Piletz, isolator of this clone, and I are currently working to confirm the signal transduction pathway of the clone, and compare it to the native receptors.
Importantly, it appears that some of our imidazoline ligands may also have neuroprotective actions. Dr. Phil Burcham of Adelaide University and myself have performed some exciting preliminary experiments that suggest these compounds may have potential as anti-Alzheimer therapies. Some of the “adduct trapping” compounds that Dr. Burcham has discovered to reverse oxidative stress-induced damage also appear to promote recovery of neurons from damage in models of Alzheimer’s disease. These results have been incorporated into Dr. Burcham’s patent PCT/AU0-2/00900.
The work on Imidazoline receptors follows on from work I began in 1991, when I was awarded an Alexander von Humboldt Research Fellowship and went to the Institute of Pharmacology at the Free University of Berlin. I worked in the laboratory of Professor Gunter Schultz, an international authority on receptor-second messenger interactions. I studied the linkage of a2‑adrenoceptor subtypes to second messenger pathways and the second messenger pathways involved in the functional response to the then newly described a2‑adrenoceptor-like imidazoline receptors. This work was continued with the award of an NH&MRC C.J. Martin Research Fellowship in 1992. .
In October 1994 I returned to Australia to work at Prince Henry's Institute of Medical Research to continue my work on imidazoline receptors and ion channels and to extend my findings from cell lines to animal models. Experiments in the corpus striatum confirmed and extended the findings from cell lines. I have shown that imidazoline receptor ligands inhibit nicotine-stimulated dopamine release with potencies and orders of affinity that reflect their affinity for the nicotinic receptors.
Prior to this I had completed a Ph.D. at the University of Melbourne on an Australian Postgraduate Award with Dr. H. Majewski and Professor M.J. Rand (Department of Pharmacology). In my doctoral work I studied the second messenger mechanisms by which prejunctional a2‑adrenoceptors and angiotensin II receptors modulate noradrenaline release from sympathetic nerves. In 1989 I submitted my Ph.D. thesis entitled: Involvement of second messenger systems in the modulation of noradrenaline release from sympathetic nerves. This study was continued on an NH&MRC grant on which I was a co-investigator on a National Health and Research Council Research Project Grant working on second messengers and the control of noradrenaline release. This work provided basic evidence for the signalling pathways operative in sympathetic nerves and the work on G-proteins was instrumental in opening debate about a2-adrenoceptor coupling processes
My Ph.D. grew out of work I performed for my Masters project. In 1980 I joined Professor R.D. Gordon's hypertension group at the Greenslopes Repatriation Hospital as a research assistant, working on a National Heart Foundation project on the effect of a low salt diet on sympathetic neurotransmission. In 1982 I enrolled in a part-time M.Sc. on the modulation of sympathetic neurotransmission under the joint supervision of Professor R.D. Gordon (Department of Medicine) and Professor B. Shanley (Department of Biochemistry). I submitted my M.Sc. thesis: Modulation of noradrenergic transmission in humans by circulating adrenaline in 1986.
Date Position Institution name 2001 Senior Lecturer University of Adelaide 1998 - 2000 Senior Research Officer Royal Melbourne Institute of Technology University 1997 Research Fellow (Wholetime Medical Specialists) Prince Henry’s Institute of Medical Research 1995 - 1996 Research Fellow (National Health and Medical Research Council C.J. Martin) Prince Henry's Institute of Medical Research 1992 - 1994 Research Fellow (National Health and Medical Research Council C.J. Martin) Institut für Molekulare Pharmakologie (LG), Freie Universität 1991 - 1992 Alexander von Humboldt Fellow Institut für Molekulare Pharmakologie (LG), Freie Universität 1989 - 1991 National Health and Medical Research Council Research Officer Department of Pharmacology 1985 Research Assistant I University of Queensland 1980 - 1984 Research Assistant II University of Queensland 1977 - 1980 Technologist B University of Queensland
Awards and Achievements
Date Type Title Institution Name Country Amount 2018 Achievement The Thornett Award for the Promotion of Reason 2018 Australian Skeptics Australia $2000 2017 Recognition Unsung hero of Science Communication SA 2017 Government of South Australia, Department of Industry and Skills Australia — 1995 Research Award Johnson and Johnson New Investigator Award Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Australia —
Language Competency German Can read, speak and understand spoken
Date Institution name Country Title 1989 University of Melbourne Australia Ph.D. 1987 University of Queensland Australia M. Sc. 1976 Queensland Institute of Technology Australia B.App.Sci.
Year Citation 2019 Farrington, R., Musgrave, I., Nash, C., Coghlan, M., & Byard, R. (2019). Evaluation of an early twentieth century Afghan herbalist’s preparations. Forensic Science, Medicine, and Pathology, 15(2), 314-318.
DOI Scopus1 WoS1
2019 Farrington, R., Musgrave, I., & Byard, R. (2019). Potential adverse outcomes of herbal preparation use in childhood. Acta Paediatrica, International Journal of Paediatrics, 108(3), 419-422.
2019 Alghazwi, M., Smid, S., Musgrave, I., & Zhang, W. (2019). In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (Aβ₁−₄₂) toxicity and aggregation. Neurochemistry International, 124, 215-224.
DOI Scopus3 WoS2 Europe PMC1
2019 Farrington, R., Musgrave, I., & Byard, R. (2019). Evidence for the efficacy and safety of herbal weight loss preparations. Journal of integrative medicine, 17(2), 87-92.
2019 Hoban, C. L., Byard, R. W., & Musgrave, I. F. (2019). Analysis of spontaneous adverse drug reactions to echinacea, valerian, black cohosh and ginkgo in Australia from 2000 to 2015.. Journal of integrative medicine, 17(5), 338-343.
2019 Crighton, E., Weisenseel, J., Bunce, M., Musgrave, I., Trengove, R., & Maker, G. (2019). Exploring the application of the DSA-TOF, a direct, high-resolution time-of-flight mass spectrometry technique for the screening of potential adulterated and contaminated herbal medicines. Journal of the American Society for Mass Spectrometry, 30(9), 1713-1719.
2019 Crighton, E., Coghlan, M., Farrington, R., Hoban, C., Power, M., Nash, C., . . . Maker, G. (2019). Toxicological screening and DNA sequencing detects contamination and adulteration in regulated herbal medicines and supplements for diet, weight loss and cardiovascular health.. J Pharm Biomed Anal, 176, 7 pages.
2019 Sun, B., Sundaraneedi, M., Southam, H., Poole, R., Musgrave, I., Keene, F., & Collins, J. (2019). Synthesis and biological properties of tetranuclear ruthenium complexes containing the bis[4(4′-methyl-2,2′-bipyridyl)]-1,7-heptane ligand. Dalton Transactions, 48(38), 14505-14515.
2019 Hoban, C., Byard, R., & Musgrave, I. (2019). Hypersensitive adverse drug reactions to glucosamine and chondroitin preparations in Australia between 2000 and 2011. Postgraduate Medical Journal.
2018 Hoban, C., Musgrave, I., Coghlan, M., Power, M., Byard, R., Nash, C., . . . Bunce, M. (2018). Adulterants and Contaminants in Psychotropic Herbal Medicines Detected with Mass Spectrometry and Next-Generation DNA Sequencing. Pharmaceutical Medicine, 32(6), 429-444.
2018 Sun, B., Musgrave, I., Day, A., Heimann, K., Keene, F., & Collins, J. (2018). Eukaryotic cell toxicity and HSA binding of [Ru(Me <inf>4</inf> phen)(bb <inf>7</inf> )] <sup>2+</sup> and the effect of encapsulation in cucurbituril. Frontiers in Chemistry, 6(NOV), 12 pages.
DOI Scopus1 WoS1
2018 Hoban, C., Nash, C., Musgrave, I., & Byard, R. (2018). An analysis of Vietnamese traditional herbal medicines for prescription and non-prescription drugs, herbicides and pesticides. Australian Journal of Forensic Sciences, 50(5), 514-520.
DOI Scopus2 WoS3
2018 Pilla, M., van den Heuvel, C., Musgrave, I., & Byard, R. (2018). Increasing incidence of nonlethal inflicted injuries in paediatric homicides: a 45-year study. Journal of Forensic and Legal Medicine, 59, 4-7.
2018 Farrington, R., Musgrave, I., Nash, C., & Byard, R. (2018). Potential forensic issues in overseas travellers exposed to local herbal products. Journal of Forensic and Legal Medicine, 60, 1-2.
2017 Byard, R., Musgrave, I., Maker, G., & Bunce, M. (2017). What risks do herbal products pose to the Australian community?. Medical Journal of Australia, 206(2), 86-90.
DOI Scopus18 WoS15 Europe PMC5
2017 O'Neill, K., Musgrave, I., & Humpage, A. (2017). Extended Low-Dose Exposure to Saxitoxin Inhibits Neurite Outgrowth in Model Neuronal Cells. Basic and Clinical Pharmacology and Toxicology, 120(4), 390-397.
DOI Scopus2 WoS2 Europe PMC1
2016 Calabrese, A., Liu, Y., Wang, T., Musgrave, I., Pukala, T., Tabor, R., . . . Bowie, J. (2016). The amyloid fibril-forming properties of the amphibian antimicrobial peptide uperin 3.5. ChemBioChem, 17(3), 239-246.
DOI Scopus8 WoS8 Europe PMC2
2016 Das, S., Stark, L., Musgrave, I., Pukala, T., & Smid, S. (2016). Bioactive polyphenol interactions with β amyloid: a comparison of binding modelling, effects on fibril and aggregate formation and neuroprotective capacity. Food & Function, 7(2), 1138-1146.
DOI Scopus20 WoS17 Europe PMC7
2016 Maiden, N., Musgrave, I., Fisk, W., & Byard, R. (2016). Pig Organ Energy Loss Comparison Experiments Using BBs. Journal of Forensic Sciences, 61(3), 679-686.
DOI Scopus5 WoS5 Europe PMC2
2016 Jayne, T., Newman, M., Verdile, G., Sutherland, G., Münch, G., Musgrave, I., . . . Lardelli, M. (2016). Evidence for and against a pathogenic role of reduced γ-secretase activity in familial Alzheimer's disease. Journal of Alzheimer's Disease, 52(3), 781-799.
DOI Scopus11 WoS11 Europe PMC9
2016 Musgrave, I., Farrington, R., Hoban, C., & Byard, R. (2016). Caffeine toxicity in forensic practice: possible effects and under-appreciated sources. Forensic Science, Medicine, and Pathology, 12(3), 299-303.
DOI Scopus8 WoS8 Europe PMC7
2016 Gransbury, G., Kappen, P., Glover, C., Hughes, J., Levina, A., Lay, P., . . . Harris, H. (2016). Comparison of KP1019 and NAMI-A in tumour-mimetic environments. Metallomics, 8(8), 762-773.
DOI Scopus21 WoS22 Europe PMC5
2016 Brinn, M., O'Neill, K., Musgrave, I., Freeman, B., Henneberg, M., & Kumaratilake, J. (2016). An optimized method for obtaining adult rat spinal cord motor neurons to be used for tissue culture. Journal of Neuroscience Methods, 273, 128-137.
2016 O'Neill, K., Musgrave, I., & Humpage, A. (2016). Low dose extended exposure to saxitoxin and its potential neurodevelopmental effects: A review. Environmental Toxicology and Pharmacology, 48, 7-16.
DOI Scopus13 WoS12 Europe PMC7
2015 Coghlan, M., Maker, G., Crighton, E., Haile, J., Murray, D., White, N., . . . Bunce, M. (2015). Combined DNA, toxicological and heavy metal analyses provides an auditing toolkit to improve pharmacovigilance of traditional Chinese medicine (TCM). Scientific Reports, 5(1), 17475-1-17475-9.
DOI Scopus34 WoS34 Europe PMC17
2015 Hoban, C., Byard, R., & Musgrave, I. (2015). A comparison of patterns of spontaneous adverse drug reaction reporting with St. John's Wort and fluoxetine during the period 2000-2013. Clinical and Experimental Pharmacology and Physiology, 42(7), 747-751.
DOI Scopus9 WoS9 Europe PMC5
2015 Moussavi Nik, S., Newman, M., Wilson, L., Ebrahimie, E., Wells, S., Musgrave, I., . . . Lardelli, M. (2015). Alzheimer's disease-related peptide PS2V plays ancient, conserved roles in suppression of the unfolded protein response under hypoxia and stimulation of γ-secretase activity. Human Molecular Genetics, 24(13), 3662-3678.
DOI Scopus13 WoS11 Europe PMC6
2014 Byard, R., Musgrave, I., Hoban, C., & Bunce, M. (2014). DNA sequencing and metabolomics: new approaches to the forensic assessment of herbal therapeutic agents. Forensic Science, Medicine, and Pathology, 11(1), 1-2.
DOI Scopus7 WoS6 Europe PMC3
2014 Gilbert, J., Musgrave, I., Hoban, C., & Byard, R. (2014). Lethal hepatocellular necrosis associated with herbal polypharmacy in a patient with chronic hepatitis B infection. Forensic Science International, 241, 138-140.
DOI Scopus5 WoS7 Europe PMC1
2014 Elias, A., Scanlon, D., Musgrave, I., & Carver, J. (2014). SEVI, the semen enhancer of HIV infection along with fragments from its central region, form amyloid fibrils that are toxic to neuronal cells. Biochimica et Biophysica Acta - Proteins and Proteomics, 1844(9), 1591-1598.
DOI Scopus8 WoS8 Europe PMC7
2014 Blacksell, L., Byard, R., & Musgrave, I. (2014). Forensic problems with the composition and content of herbal medicines. Journal of Forensic and Legal Medicine, 23, 19-21.
DOI Scopus6 WoS6 Europe PMC2
2014 Liu, Y., Carver, J., Ho, L., Elias, A., Musgrave, I., & Pukala, T. (2014). Hemin as a generic and potent protein misfolding inhibitor. Biochemical and Biophysical Research Communications, 454(2), 295-300.
DOI Scopus13 WoS12 Europe PMC4
2013 Lloyd, H., Hinton, T., Bullock, S., Babey, A., Davis, E., Fernandes, L., . . . Ziogas, J. (2013). An evaluation of pharmacology curricula in Australian science and health-related degree programs. BMC Medical Education, 13(1), 1-15.
DOI Scopus7 WoS6 Europe PMC1
2013 Liu, Y., Pukala, T., Musgrave, I., Williams, D., Dehle, F., & Carver, J. (2013). Gallic acid is the major component of grape seed extract that inhibits amyloid fibril formation. Bioorganic & Medicinal Chemistry Letters, 23(23), 6336-6340.
DOI Scopus56 WoS54 Europe PMC29
2013 Wong, D., Musgrave, I., Harvey, B., & Smid, S. (2013). Açaí (Euterpe oleraceae Mart.) berry extract exerts neuroprotective effects against β-amyloid exposure in vitro. Neuroscience Letters, 556, 221-226.
DOI Scopus21 WoS19 Europe PMC11
2013 Rahman, S., Basilakis, J., Rahmadi, A., Lujic, S., Musgrave, I., Jorm, L., . . . Munch, G. (2013). Use of serotonergic antidepressants and St John's wort in older Australians: A population-based cohort study. Australasian Psychiatry, 21(3), 262-266.
DOI Scopus6 WoS4 Europe PMC3
2012 Calabrese, A., Markulic, K., Musgrave, I., Guo, H., Zhang, L., & Bowie, J. (2012). Structural and activity changes in three bioactive anuran peptides when Asp is replaced by isoAsp. Peptides, 38(2), 427-436.
DOI Scopus1 WoS1
2012 Smid, S., Maag, J., & Musgrave, I. (2012). Dietary polyphenol-derived protection against neurotoxic β-amyloid protein: from molecular to clinical. Food & Function: linking the chemistry and physics of food with health and nutrition, 3(12), 1242-1250.
DOI Scopus41 WoS39 Europe PMC18
2012 Koudelka, T., Dehle, F., Musgrave, I., Hoffmann, P., & Carver, J. (2012). Methionine oxidation enhances κ-casein amyloid fibril formation. Journal of Agricultural and Food Chemistry, 60(16), 4144-4155.
DOI Scopus18 WoS19 Europe PMC7
2012 Weekley, C., Aitken, J., Musgrave, I., & Harris, H. (2012). Methylselenocysteine treatment leads to diselenide formation in human cancer cells: evidence from X-ray absorption spectroscopy studies. Biochemistry, 51(3), 736-738.
DOI Scopus16 WoS15 Europe PMC8
2012 Moussavi Nik, S., Wilson, L., Newman, M., Croft, K., Mori, T., Musgrave, I., & Lardelli, M. (2012). The BACE1-PSEN-AβPP regulatory axis has an ancient role in response to low oxygen/oxidative stress. Journal of Alzheimer's Disease, 28(3), 515-530.
DOI Scopus24 WoS16 Europe PMC18
2012 Harvey, B., Ohlsson, K., Maag, J., Musgrave, I., & Smid, S. (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. Neurotoxicology, 33(1), 138-146.
DOI Scopus40 WoS36 Europe PMC23
2012 Wilkins, J., Stanyon, C., & Musgrave, I. (2012). Selection without replicators: the origin of genes, and the replicator/interactor distinction in etiobiology. Biology & Philosophy, 27(2), 215-239.
DOI Scopus1 WoS1
2011 Weekley, C., Aitken, J., Vogt, S., Finney, L., Paterson, D., De Jonge, M., . . . Harris, H. (2011). Metabolism of selenite in human lung cancer cells: X-ray absorption and fluorescence studies. Journal of the American Chemical Society, 133(45), 18272-18279.
DOI Scopus49 WoS48 Europe PMC26
2011 Harvey, B., Musgrave, I., Ohlsson, K., Fransson, A., & Smid, S. (2011). The green tea polyphenol (−)-epigallocatechin-3-gallate inhibits amyloid-β evoked fibril formation and neuronal cell death in vitro. Food Chemistry, 129(4), 1729-1736.
DOI Scopus29 WoS26 Europe PMC17
2011 Weekley, C., Aitken, J., Vogt, S., Finney, L., Paterson, D., De Jonge, M., . . . Harris, H. (2011). Uptake, distribution, and speciation of selenoamino acids by human cancer cells: X-ray absorption and fluorescence methods. Biochemistry, 50(10), 1641-1650.
DOI Scopus36 WoS32 Europe PMC20
2011 Ellis-Steinborner, S., Scanlon, D., Musgrave, I., Tran, T., Hack, S., Wang, T., . . . Bowie, J. (2011). An unusual kynurenine-containing opioid tetrapeptide from the skin gland secretion of the Australian red tree frog Litoria rubella. Sequence determination by electrospray mass spectrometry. Rapid Communications in Mass Spectrometry, 25(12), 1735-1740.
DOI Scopus5 WoS5 Europe PMC4
2011 Lyachev, A., Musgrave, I., Tang, Y., Hernandez-Gomez, C., Ross, I., Galimberti, M., . . . Collier, J. (2011). Development of a novel large bandwidth front-end system for high peak power OPCPA systems. OPTICS EXPRESS, 19(17), 15824-15832.
DOI WoS11 Europe PMC2
2010 Dehle, F., Ecroyd, H., Musgrave, I., & Carver, J. (2010). αB-Crystallin inhibits the cell toxicity associated with amyloid fibril formation by κ-casein and the amyloid-β peptide. Cell Stress & Chaperones, 15(6), 1013-1026.
DOI Scopus43 WoS40 Europe PMC20
2010 Byard, R., & Musgrave, I. (2010). Herbal medicines and forensic investigations. Forensic Science, Medicine, and Pathology, 6(2), 81-82.
DOI Scopus14 WoS13 Europe PMC7
2010 Ingman, W., McGrath, L., Breed, W., Musgrave, I., Robker, R., & Robertson, S. (2010). The mechanistic basis for sexual dysfunction in male transforming growth factor β1 null mutant mice. Journal of Andrology, 31(2), 95-107.
DOI Scopus3 WoS3 Europe PMC1
2009 Hudson, S., Ecroyd, H., Dehle, F., Musgrave, I., & Carver, J. (2009). (-)-Epigallocatechin-3-gallate (EGCG) Maintains k-Casein in its pre-fibrillar state without redirecting its aggregation pathway. Journal of Molecular Biology, 392(3), 689-700.
DOI Scopus102 WoS97 Europe PMC55
2009 Bilusich, D., Jackway, R., Musgrave, I., Tyler, M., & Bowie, J. (2009). The host-defence skin peptide profiles of Peron's Tree Frog Litoria peronii in winter and summer. Sequence determination by electrospray mass spectrometry and activities of the peptides. Rapid Communications in Mass Spectrometry, 23(17), 2628-2636.
DOI Scopus12 WoS9 Europe PMC6
2009 Sherman, P., Jackway, R., Nicholson, E., Musgrave, I., Boontheung, P., & Bowie, J. (2009). Activities of seasonably variable caerulein and rothein skin peptides from the tree frogs Litoria splendida and Litoria rothii. Toxicon, 54(6), 828-835.
DOI Scopus9 WoS7 Europe PMC4
2009 Jackway, R., Maselli, V., Musgrave, I., Maclean, M., Tyler, M., & Bowie, J. (2009). Skin peptides from anurans of the Litoria rubella Group: sequence determination using electrospray mass spectrometry. Opioid activity of two major peptides. Rapid Communications in Mass Spectrometry, 23(8), 1189-1195.
DOI Scopus11 WoS10 Europe PMC5
2008 Jackway, R., Pukala, T., Maselli, V., Musgrave, I., Bowie, J., Liu, Y., . . . Tyler, M. (2008). Disulfide-containing peptides from the glandular skin secretions of froglets of the genus Crinia: Structure, activity and evolutionary trends. Regulatory Peptides, 151(1-3), 80-87.
DOI Scopus9 WoS8 Europe PMC5
2008 Jackway, R., Bowie, J., Bilusich, D., Musgrave, I., Surinya, K., Tyler, M., & Eichinger, P. (2008). The fallaxidin peptides from the skin secretion of the Eastern Dwarf Tree Frog Litoria fallax. Sequence determination by positive and negative ion electrospray mass spectrometry: antimicrobial activity and cDNA cloning of the fallaxidins. Rapid Communications in Mass Spectrometry, 22(20), 3207-3216.
DOI Scopus11 WoS10 Europe PMC5
2008 Musgrave, I. (2008). Moth myths. New Scientist, 197(2638), 19.
2007 Newman, M., Musgrave, I., & Lardelli, M. (2007). Alzheimer disease: amyloidogenesis, the presenilins and animal models. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1772(3), 285-297.
DOI Scopus104 WoS92 Europe PMC55
2007 Newman, M., Musgrave, I., & Lardelli, M. (2007). Corrigendum to "Alzheimer disease: Amyloidogenesis, the presenilins and animal models" [Biochim. Biophys. Acta 1772 (2007) 285-297] (DOI:10.1016/j.bbadis.2006.12.001). Biochimica et Biophysica Acta - Molecular Basis of Disease, 1772(9), 1118.
2006 Pukala, T., Bowie, J., Maselli, V., Musgrave, I., & Tyler, M. (2006). Host-defence peptides from the glandular secretions of amphibians: structure and activity. Natural Product Reports, 23(3), 368-393.
DOI Scopus160 WoS147 Europe PMC96
2006 Powell, M., Barnes, N., Bradford, T., Musgrave, I., Wines, B., Cambier, J., & Hogarth, P. (2006). Alteration of the Fc[gamma]RIIa dimer interface affects receptor signaling but not ligand binding. Journal of Immunology, 176(12), 7489-7494.
DOI Scopus26 WoS24 Europe PMC19
2006 Pukala, T. L., Bowie, J. H., Maselli, V. M., Musgrave, I. F., & Tyler, M. J. (2006). Host-Defence Peptides from the Glandular Secretions of Amphibians: Structure and Activity. ChemInform, 37(37).
2005 Spier, R., Musgrave, I., Kirk, S., & Callaghan, T. (2005). Unintelligent design  (multiple letters). New Scientist, 187(2509), 20. 2005 Baudinette, R., Boontheung, P., Musgrave, I., Wabnitz, P., Maselli, V., Skinner, J., . . . Bowie, J. (2005). An immunomodulator used to protect young in the pouch of the Tammar wallaby, Macropus eugenii. FEBS Journal, 272(2), 433-443.
DOI Scopus17 WoS17 Europe PMC13
2003 Musgrave, I., Dehle, F., & Piletz, J. (2003). Assembly of PRR-containing receptors on scaffolds: a model for imidazoline I1-receptor action. Annals of the New York Academy of Sciences, 1009(1), 413-418.
DOI Scopus3 WoS2 Europe PMC2
2003 Musgrave, I., van der Zypp, A., Grigg, M., & Barrow, C. (2003). Endogenous imidazoline receptor ligands relax rat aorta by an endothelium-dependent mechanism. Annals of the New York Academy of Sciences, 1009(1), 222-227.
DOI Scopus7 WoS7 Europe PMC5
2000 Musgrave, I., & Badoer, E. (2000). Harmane produces hypotension following microinjection into the RVLM: Possible role of I<inf>1</inf>-imidazoline receptors. British Journal of Pharmacology, 129(6), 1057-1059.
DOI Scopus55 WoS53 Europe PMC29
1999 Musgrave, I., & Hughes, R. (1999). Novel targets and techniques in imidazoline receptor research. Annals of the New York Academy of Sciences, 881(1 IMIDAZOLINE R), 301-312.
DOI Scopus10 WoS9 Europe PMC7
1998 Musgrave, I., & Hughes, R. (1998). Investigation of I<inf>1</inf>-imidazoline receptors using microphysiometry and molecular modelling. Journal of the Autonomic Nervous System, 72(2-3), 137-146.
DOI Scopus5 WoS5 Europe PMC4
1998 Grigg, M., Musgrave, I., & Barrow, C. (1998). Isolation and partial structure determination of a clonidine-displacing substance from bovine lung and brain. Journal of the Autonomic Nervous System, 72(2-3), 86-93.
DOI Scopus7 WoS7 Europe PMC6
1998 Head, G., Gundlach, A., & Musgrave, I. (1998). Recent advances in imidazoline receptor research: Ligands-localization and isolation-signaling-functional and clinical studies. Journal of the Autonomic Nervous System, 72(2-3), 74-79.
DOI Scopus11 WoS8 Europe PMC8
1998 Chen, C., Farnworth, P., Petersenn, S., Musgrave, I., Canny, B., & Clarke, L. (1998). Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells. Endocrine, 9(1), 71-77.
DOI Scopus6 WoS11 Europe PMC2
1998 Musgrave, I. (1998). Structure and function of protein kinases and protein phosphatases.. IDrugs : the investigational drugs journal, 1(6), 617-619.
1998 Head, G., Gundlach, A., & Musgrave, I. (1998). Special issue: Imidazoline receptors - Imidazoline Receptor Workshop, 10 September 1997, Melbourne, Australia - Introduction. JOURNAL OF THE AUTONOMIC NERVOUS SYSTEM, 72(2-3), 73. 1998 Musgrave, I., Kotsopoulos, D., & Hughes, R. (1998). Ion channel modulators and I-1-imidazoline binding sites in bovine adrenal medulla.. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 358(1), R560. 1998 Editorial (1998). Journal of the Autonomic Nervous System, 72(2-3), 73.
1997 Majewski, H., Kotsonis, P., Iannazzo, L., Murphy, T., & Musgrave, I. (1997). Protein kinase C and transmitter release. Clinical and Experimental Pharmacology and Physiology, 24(8), 619-623.
DOI Scopus15 WoS16 Europe PMC11
1996 Wenzel-Seifert, K., Krautwurst, D., Musgrave, I., & Seifert, R. (1996). Thapsigargin activates univalent- and bivalent-cation entry in human neutrophils by a SK&F 96365- and Gd<sup>3+</sup>-sensitive pathway and is a partial secretagogue: Involvement of pertussis-toxin-sensitive G-proteins and protein phosphatases 1/2A and 2B in the signal-transduction pathway. Biochemical Journal, 314(2), 679-686.
DOI Scopus27 WoS26 Europe PMC16
1995 Musgrave, I., & Seifert, R. (1995). α<inf>2A</inf>-adrenoceptors mediate activation of non-selective cation channels via G<inf>i</inf>-proteins in human erythroleukaemia (HEL) cells. No evidence for a functional role of imidazoline receptors in modulating calcium. Biochemical Pharmacology, 49(2), 187-196.
DOI Scopus21 WoS22 Europe PMC15
1995 Schroeder, G., Kotsonis, P., Musgrave, I., & Majewski, H. (1995). Protein kinase C involvement in maintenance and modulation of noradrenaline release in the mouse brain cortex. British Journal of Pharmacology, 116(6), 2757-2763.
DOI Scopus16 WoS16 Europe PMC12
1995 MUSGRAVE, I., KRAUTWURST, D., HESCHELER, J., & SCHULTZ, G. (1995). Clonidine and Cirazoline Inhibit Activation of Nicotinic Channels in PC‐12 Cells. Annals of the New York Academy of Sciences, 763(1), 272-282.
DOI Scopus21 Europe PMC8
1995 Musgrave, I., & Seifert, R. (1995). Alpha 2A-adrenoceptors mediate activation of non-selective cation channels via Gi-proteins in human erythroleukaemia (HEL) cells. No evidence for a functional role of imidazoline receptors in modulating calcium.. Biochem Pharmacol, 49(2), 187-196.
1994 Musgrave, I., & Seifert, R. (1994). Human neutrophils and HL-60 cells do not possess α2-adrenoceptors. Biochemical Pharmacology, 47(2), 233-239.
DOI Scopus11 WoS11 Europe PMC7
1994 Musgrave, I., Seifert, R., & Schultz, G. (1994). Maitotoxin activates cation channels distinct from the receptor-activated non-selective cation channels of HL-60 cells. Biochemical Journal, 301(2), 437-441.
DOI Scopus36 WoS36 Europe PMC22
1994 MUSGRAVE, I., SEIFERT, R., & SCHULTZ, G. (1994). MATIOTOXIN STIMULATES CALCIUM INFLUX IN HL-60 CELLS THROUGH A PATHWAY DISTINCT FROM RECEPTOR-ACTIVATED NONSELECTIVE CATION CHANNELS. BRITISH JOURNAL OF PHARMACOLOGY, 112, U214. 1993 Musgrave, I., Genieser, H., Maronde, E., & Seifert, R. (1993). Preparations of Rp-cyclic adenosine 3',5'-phosphorothioate (Rp-cAMPS) can contain biologically active amounts of adenosine. FEBS Letters, 318(3), 227-230.
DOI Scopus6 WoS5 Europe PMC3
1991 Musgrave, I., Foucart, S., & Majewski, H. (1991). Evidence that angiotensin II enhances noradrenaline release from sympathetic nerves in mouse atria by activating protein kinase C. Journal of Autonomic Pharmacology, 11(4), 211-220.
DOI Scopus28 WoS29 Europe PMC14
1991 Foucart, S., Musgrave, I., & Majewski, H. (1991). Long term treatment with phorbol esters suggests a permissive role for protein kinase C in the enhancement of noradrenaline release. Molecular Neuropharmacology, 1(3), 95-101.
1990 Foucart, S., Musgrave, I., & Majewski, H. (1990). Inhibition of noradrenaline release by neuropeptide Y does not involve protein kinase C in mouse atria. Neuropeptides, 15(4), 179-185.
DOI Scopus10 WoS12 Europe PMC8
1990 MAJEWSKI, H., COSTA, M., FOUCART, S., MURPHY, T., & MUSGRAVE, I. (1990). Second Messengers Are Involved in Facilitatory but Not Inhibitory Receptor Actions at Sympathetic Nerve Endings. Annals of the New York Academy of Sciences, 604(1), 266-275.
DOI Scopus18 Europe PMC7
1990 MUSGRAVE, I., FOUCART, S., & MAJEWSKI, H. (1990). ANGIOTENSIN-II ENHANCES NORADRENALINE RELEASE FROM SYMPATHETIC-NERVES THROUGH ACTIVATION OF PROTEIN-KINASE-C. BLOOD VESSELS, 27(1), 50. 1990 Musgrave, I., Foucart, S., & Majewski, H. (1990). Angiotensin II enhances stimulation-induced noradrenaline release from sympathetic nerves through protein kinase C. European Journal of Pharmacology, 183(4), 1486-1487.
1990 MAJEWSKI, H., COSTA, M., FOUCART, S., MURPHY, T., & MUSGRAVE, I. (1990). 2ND MESSENGERS ARE INVOLVED IN FACILITATORY BUT NOT INHIBITORY RECEPTOR ACTIONS AT SYMPATHETIC-NERVE ENDINGS. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 604, 266-275.
1989 Majewski, H., & Musgrave, I. (1989). G proteins and α-adrenoceptor classification. Trends in Pharmacological Sciences, 10(1), 14.
DOI Scopus1 WoS3
1989 Musgrave, I., Foucart, S., & Majewski, H. (1989). Do phorbol myristate and phorbol dibutyrate enhance noradrenaline release by the same mechanisms?. British journal of pharmacology, 98 Suppl, 776P.
Scopus3 Europe PMC2
1989 Rajanayagam, M., Musgrave, I., Rand, M., & Majewski, H. (1989). Facilitation of noradrenaline release by isoprenaline is not mediated by angiotensin II in mouse atria and rat tail artery. Archives Internationales de Pharmacodynamie et de Therapie, 299, 185-199.
Scopus13 WoS14 Europe PMC9
1989 Musgrave, I., & Majewski, H. (1989). Effect of phorbol ester and pertussis toxin on the enhancement of noradrenaline release by angiotensin II in mouse atria. British Journal of Pharmacology, 96(3), 609-616.
DOI Scopus21 WoS23 Europe PMC20
1989 Musgrave, I., & Majewski, H. (1989). Effect of phorbol esters and polymyxin B on modulation of noradrenaline release in mouse atria. Naunyn-Schmiedeberg's Archives of Pharmacology, 339(1), 48-53.
DOI Scopus30 WoS30 Europe PMC12
1987 Musgrave, I., Marley, P., & Majewski, H. (1987). Pertussis toxin does not attenuate α<inf>2</inf>-adrenoceptor mediated inhibition of noradrenaline release in mouse atria. Naunyn-Schmiedeberg's Archives of Pharmacology, 336(3), 280-286.
DOI Scopus40 WoS53 Europe PMC23
1987 Johnston, H., Majewski, H., & Musgrave, I. (1987). Involvement of cyclic nucleotides in prejunctional modulation of noradrenaline release in mouse atria. British Journal of Pharmacology, 91(4), 773-781.
DOI Scopus49 WoS52 Europe PMC44
1985 Musgrave, I., Bachmann, A., Jackson, R., & Gordon, R. (1985). INCREASED PLASMA NORADRENALINE DURING LOW DOSE ADRENALINE INFUSION IN RESTING MAN AND DURING SYMPATHETIC STIMULATION. Clinical and Experimental Pharmacology and Physiology, 12(3), 285-289.
DOI Scopus24 WoS31 Europe PMC16
1984 Musgrave, I., Bachmann, A., Saar, N., & Gordon, R. (1984). A comparison of cardiovascular and catecholamine responses to three stimuli in mild hypertension. Metabolism, 33(8), 718-723.
DOI Scopus17 WoS17 Europe PMC10
1984 Musgrave, I., Bachmann, A., & Gordon, R. (1984). Increased plasma noradrenaline during adrenaline infusion in man. Journal of Hypertension, 2(SUPPL. 3), 135-137.
1984 Musgrave, I., Bachmann, A., & Gordon, R. (1984). Increased plasma noradrenaline during adrenaline infusion in man.. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2(3), S135-S137.
Year Citation 2013 Smid, S., & Musgrave, I. (2013). Dietary polyphenols as inhibitors of Β-amyloid-evoked neurotoxicity: implications for the treatment of Alzheimer's disease. In J. Sun, K. Prasad, A. Ismail, B. Yang, X. You, & L. Li (Eds.), Polyphenols: Chemistry, Dietary Sources and Health Benefits (1 ed., pp. 521-538). United States: Nova Science Publishers. 1990 Myles, G. (1990). Introduction. In G. Myles (Ed.), Measurement and Modelling in Economics (Vol. 72, pp. 461 pages). Elsevier.
Year Citation 1996 Musgrave, I., Krautwurst, D., & Schultz, G. (1996). Imidazoline binding sites and signal transduction pathways. In Clinical and Experimental Pharmacology and Physiology Vol. 23 (pp. 990-994). ADELAIDE, AUSTRALIA: BLACKWELL SCIENCE.
DOI Scopus16 WoS17 Europe PMC11
1995 Majeuiski, H., & Musgrave, I. (1995). Second messenger pathways in the modulation of neurotransmitter release. In Australian and New Zealand Journal of Medicine Vol. 25 (pp. 817-821). CENTENARY INST MED & CELL BIOL, SYDNEY, AUSTRALIA: ADIS PRESS AUSTRALASIA P/L.
DOI Scopus8 WoS9 Europe PMC5
1990 MAJEWSKI, H., COSTA, M., FOUCART, S., MURPHY, T., & MUSGRAVE, I. (1990). 2ND MESSENGERS ARE INVOLVED IN FACILITATORY BUT NOT INHIBITORY RECEPTOR ACTIONS AT SYMPATHETIC-NERVE ENDINGS. In S. KALSNER, & T. WESTFALL (Eds.), PRESYNAPTIC RECEPTORS AND THE QUESTION OF AUTOREGULATION OF NEUROTRANSMITTER RELEASE Vol. 604 (pp. 266-275). PHILADELPHIA, PA: NEW YORK ACAD SCIENCES.
Year Citation 2015 Smid, S., Das, S., Musgrave, I., & Pukala, T. (2015). Bioactive polyphenol interactions with beta amyloid: a comparison of binding, fibril inhibition and neuroprotection. Poster session presented at the meeting of JOURNAL OF NEUROCHEMISTRY. Cairns, AUSTRALIA: WILEY-BLACKWELL. 2014 O'Neill, K., & Musgrave, I. (2014). The effect of saxitoxin on the differentiation of D3 embryonic stem cells into a neural lineage. Poster session presented at the meeting of TOXICOLOGY LETTERS. Edinburgh, SCOTLAND: ELSEVIER IRELAND LTD.
2011 Smid, S., Salem, A., & Musgrave, I. (2011). Blended learning approaches to practical teaching in pharmacology: the best of both worlds?. Poster session presented at the meeting of Transformation. Adelaide, Australia. 2010 Salem, A., Smid, S., Musgrave, I., & Carrington, A. (2010). Development and integration of web-based pharmacology e-resources designed to provide immediate feedback and interactive help. Poster session presented at the meeting of The Education Research Group of Adelaid. Adelaide, Australia: The University of Adelaide.
|Date||Project/ No.||Investigators||Funding Body|
|2018||“Anticoagulant rodenticide excretion in rats following median lethal dose (LD50) administration”||Hamilton, Jolley, Howard, Musgrave||Australian Pork Limited Project 2018/0011|
|2018||‘More than providing a microphone: Establishing a research cluster for public engagement with STEM research and policy'||Ankeny R et al.,||Interdisciplinary Research Fund. (University of Adelaide Internal Grant)|
|Australian Pork Limited "rodenticide feeding study in rats"||Hamilton, Jolley, Howard, Musgrave||Australian Pork Limited APL Project 2016/2230|
|In vitro toxicology assessment of herbal medicines.||Maker et al.||Murdoch University Small Grant|
|2014||Development of 'omics-based approaches to investigate labelling accuracy and legality of herbal medicine in Australia||Bunce M et al.||NHMRC APP1061329|
|2013||Structure function relationships of anti-amyloid drugs: verification in an in-vivo model.||Musgrave IF, Smid SD, Pukala T, O’Keefe L||Interdisciplinary Research Fund (University of Adelaide Internal Grant)|
Development and integration of software for practicum delivery and assessment in third year pharmacology courses
|Smid SD, Salem A, Musgrave IF||University of Adelaide Internal Grant|
Enzymatic synthesis, microencapsulation and biological evaluation of a new class of omega-3 derivedfunctional food ingredients.
|Barrow et al.||ARC Linkage Grant LP100100069|
|2009||New drug treatments for Alzhemier’s disease||Smid SD, Musgrave IF||Sunshine Foundation Grant|
|2009||Development and evaluation of on-line assessment materials for a second year compulsory course within the Bachelor of Health Sciences program||Salem A, Smid SD, Musgrave IF, Carrington A||University of Adelaide Internal Grants|
|2007||Ensuring Quality Graduates of Pharmacology||ALTC (formerly Carrick) Education Grant (member of ASCEPT Education consortium)|
|Ingman W, Musgrave IF, and Robertson SA||Faculty Small Grant|
|2006||Ingman W, Musgrave IF, and Robertson SA||Faculty Small Grant|
|2004||Burcham P, Musgrave IF||SA Brain Foundation Grant|
|2004||Musgrave IF, Piletz J and Head G||University of Adelaide, Faculty of Health Sciences Small Grants|
|Musgrave IF||University of Adelaide, Faculty of Health Sciences Travelling Fellowship Grant for Professor John Piletz|
|2003||Musgrave IF||SA Brain Foundation grant|
|2002||Musgrave IF et al.||Rebecca Cooper Foundation grant|
|2001||Musgrave IF||Adelaide University, B3 New Appointment grant|
|1999||Identification of a new endogenous ligand for imidazoline receptors.||Barrow C, Musgrave IF||ARC small grant|
|1999||Electrophysiology –Single cell fluorescence setup||Majewski H, Chen C, Musgrave IF, Li C-G, Badoer E||Wellcome Trust Equipment Grant|
Imidazoline receptors and modulation of ion channels
|Musgrave IF||NH&MRC project grant 981123|
|1995||Imidazoline receptors modulate nicotinic ion channels.||Musgrave IF||Ramaciotti Foundation Grant|
|1992||Musgrave IF||NH&MRC CJ Martin Fellowship|
|1990||Musgrave IF||Alexander Von Humboldt Fellowship|
|1989||Role of PKC on sympathetic transmitter release||Majewski H & Musgrave IF||NH&MRC Project grant|
|2013-present||Course coordinator PHARM 3010 Drug Action and Discovery|
|2013-present||Course co-ordinator, Dental& Health Science III and IV (Pharmacology Stream)|
|2010-2011||Course coordinator Drug Discovery and Development (PHARM 4200 and lecturer)|
|2008-present||Lecturing for B. Pharm Eng. PHARM 2002 and 2003 rebadged as PHARM 2100 and PHARM 2200, Course coordinator, lecturer and workshop leader PHARM 2200, Drugs Chemicals and the Environment|
Course co-ordinator, Dental& Health Science IV (Pharmacology Stream)
|2007-present||Lecturer in nursing courses, tutor in Dental& Health Science IV (Pharmacology Stream).|
|2006-present||Course coordinator, 2nd year courses (PHARM 2002, 2003, Drugs Chemicals and Health and Drugs Chemicals and the Environment respectively). Lecturer, tutor and demonstrator in 2nd, 3rd year BSc.BHealth Sc. Courses (PHARM 2002, 2003, 3010, 3011). Workshop leader in 2nd year courses, B.Health Sc|
Course co-ordinator, 3rd year second semester courses, Pharmacology BIII, B.Sc. 2004. Concepts in Pharmacology BIII and Research Methods in Pharmacology BIII B.Health Sc. 2004; Lecturer, tutor and demonstrator in 3rd year BSc.BHealth Sc. courses. Workshop participant in Fundamentals in Drug Development 3rd year BHealth Sc. Lecturer, tutor, workshop leader in 2nd year course, B.Health Sc.
|2002-2003||Course co-ordinator, 3rd year second semester course, Advanced topics in Pharmacology, B.Sc. B.Health Sc. 2003. Lecturing, tutoring and practical class co-ordination, third year basic and advanced pharmacology course B.Sc. B.Health Sc. Lecturer, tutor, workshop leader in 2nd year course, B.Health Sc|
Lecturing, tutoring and practical class co-ordination, third year basic and advanced pharmacology course. Department of Clinical and Experimental Pharmacology, Adelaide University: B.Sc. B.Health Sc.
Lecturing, and practical class demonstrating, Department of Medical Laboratory Science, RMIT University: B App Sc.
|1991-1998||Lecturing, and practical class demonstrating, Department of Pharmacology, Monash University: BSc (Hons), BSc|
|1987-1990||Lecturing, tutoring and practical class demonstrating Department of Pharmacology, University of Melbourne BSc (Hons), BSc, Dentistry, Medicine|
|2016||Invited speaker, 3D visualisations of drug-receptor interactions|
|2011||Invited Speaker, ASCEPT Education Workshop (Perth): speaking on Physical Theatre as a metod of student engagement|
|2010||Presentation of ALTC (formerly Carrick) grant “Ensuring Quality Graduates of Pharmacology” material at WorldPharma|
|2009||Finalised report on the ALTC (formerly Carrick) grant “Ensuring Quality Graduates of Pharmacology Member, ASCEPT Mentoring scheme|
Invited Speaker, ASCEPT Education Workshop (Sydney): speaking on Votapedia as a novel assessment tool
|2007-present||Carrick Education Grant team member|
|2007-present||Member ASCEPT Education Special Interest Group|
|2007||Participant, ASCEPT Teaching Workshop|
|2006-2007||Colleague Development Program participant|
|2006||HARC mentoring round table|
|2003||Teaching at University Course|
|2003||Member of ASCEPT core curriculum development group|
|2001-present||Various service courses for using MyUni|
Other Teaching Service
2006 -2009 Member Teacher Twinning Group (support to high School Science Teachers)
|2009-2012||School Honours Coordinator|
|2007-2008||Convenor School Research Committee (School RQF coordinator, ERA response co-ordinator, submission of responses to State Gov’t inquiry into the future of research in South Australia, coordinator School Grant Review process)|
|2007-present||Member OH&S Committee|
|2006-2012||Member School Research Committee|
|2006-2013||Open Day co-ordinator for Discipline, then School|
|2009-2012||Discipline honours Co-ordinator, Teaching and Learning committee|
|2007-2008||B. Pharm Eng course development. Teaching and Learning committee, Marketting Committee|
|2006||Seminar co-ordinator, Teaching and Learning committee, B. Pharm Eng development. Marketting Committee|
|2005||Seminar co-ordinator, Teaching and Learning committee, third year development group. Open day co-ordinator.|
|2004||Seminar co-ordinator, Teaching and Learning committee, third year development group. Open day co-ordinator|
|2003||Seminar co-ordinator, Equipment committee, Teaching and Learning committee, third year development group, Open day co-ordinator, ASMR research day co-ordinator.|
ASMR research day co-ordinator.
|2001||Departmental Research Committee, Faculty of Science board, Second year development group|
|2000||RMIT Departmental seminar organiser|
|1999-2000||Drug Research and Development Group management committee|
|1999-2000||Medical Laboratory Science Research Committee|
|1994-1998||Prince Henry's Institute of Medical Research, Institute Scientific Group (Chairman: 1995-1996)|
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2018 Principal Supervisor Inflammatory profiles in human neurodegenerative diseases: a study of common patterns, potential biomarkers and pathogenic mechanisms Doctor of Philosophy Doctorate Full Time Miss Anuradha Subashini Tennakoon 2017 Co-Supervisor Small Molecules and Natural Products as Inhibitors of Amyloid Aggregation and Neurotoxicity Doctor of Philosophy Doctorate Full Time Mr Dylan Thomas Marsh 2017 Principal Supervisor Herb-Herb Interactions in Drug-induced Hepatotoxicity Doctor of Philosophy Doctorate Full Time Miss Susan Marie Britza 2013 Principal Supervisor Analysis of Adverse Reactions to Herbal Medicines, Synthetic Medicines and Supplements in Australian Populations Doctor of Philosophy Doctorate Part Time Mrs Claire Louise Hoban
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2016 - 2019 Principal Supervisor Herbal Medicine Toxicity, the Role of Adulterants, Contaminants and Pharmokinetic Interactions Doctor of Philosophy Doctorate Full Time Miss Rachael Louise Farrington 2015 - 2018 Co-Supervisor Small molecular inhibitors of Amyloid beta and alpha Synuclein amyloidogenic aggregation, toxicity and in silico design of amyloid-binding ligands Doctor of Philosophy Doctorate Full Time Mrs Sukanya Das 2013 - 2018 Co-Supervisor A Comparative Study of Physiological and Modulators of Aquaporin ion Channels in Diverse Phyla Doctor of Philosophy Doctorate Full Time Mohamad Kourghi 2012 - 2017 Principal Supervisor The Effect of the Cyanobacterial Toxin Saxitoxin on Neurodevelopment Doctor of Philosophy Doctorate Full Time Katie O'Neill 2011 - 2015 Co-Supervisor The Functional Studies of Amyloid Fibrils and their Toxicity Doctor of Philosophy Doctorate Full Time Abigail Kegomoditswe Elias 2010 - 2011 Co-Supervisor Characterization of the zebrafish Orthologue of Klotho Master of Science Master Full Time Mr Yuya Sugano 2010 - 2014 Co-Supervisor The Effect of Cannabinoids on Cytokine Evoked Human Colonic Mucosal Damage and Caco-2 Epithelial Permeability Doctor of Philosophy Doctorate Full Time Mr Benjamin Harvey 2005 - 2010 Co-Supervisor Genotoxicity Investigation of Organic N-Chloramines Doctor of Philosophy Doctorate Full Time Mr Somprasong Laingam 2004 - 2008 Principal Supervisor Imidazoline Receptor Antisera - Selected Protein: A Unique Modulator of Neuronal Differentiation Doctor of Philosophy Doctorate Part Time Mr Francis Dehle
Date Role Board name Institution name Country 2013 - ongoing Director Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists management board Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Australia
Date Role Committee Institution Country 2019 - ongoing Member ASCEPT Scientific Organising Comittee Australasian Society for Clinical and Experimental Pharmacology and Toxicology Australia 2019 - 2022 Member International Union of Toxicology Nominating Committee International Union of Toxicology United States 2016 - ongoing Member Occupational Helath and Safety Comittee University of Adelaide Australia 2012 - ongoing Member Australian Science Communicators South Australian Branch — — 2010 - ongoing Chair Toxicology Special Interest Group Australian Society of Clinical and Experimental Pharmacologists and Toxicologist Australia 2009 - 2010 Member Aging Research Round Table State Office for the Ageing, Department for Families and Communities Australia 2009 - 2010 Member Toxicology Special Interest Group Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Australia 2007 - 2010 Member Adelaide Healthy Ageing Research Cluster Healthy Ageing Research Cluster Australia 2004 - 2006 Member Interim Management Group Adelaide Healthy Ageing Research Cluster (HARC) Australia
Date Role Membership Country 2019 - ongoing Member High Blood Pressure Research Council of Australia Australia 2019 - ongoing Member Forensic and Clinical Toxicology Association Australia 1995 - ongoing Member Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Australia 1995 - ongoing Member Australasian Neuroscience Society Australia
Date Institution Department Organisation Type Country 2019 - 2019 SA health Systems Performance and Service Delivery Health services and related Australia 2018 - 2019 Commonwealth of Australia Senate RURAL AND REGIONAL AFFAIRS AND TRANSPORT REFERENCES COMMITTEE Legislative and political Australia 2018 - 2018 Consumer and Business Services (CBS), South Australia Product safety section Health services and related Australia
Date Office Name Institution Country 2019 - 2021 Nominating comittee International Union of Toxicologists United States 2010 - ongoing Chair, Toxicology Special Interest group Australasian Society of Clinical and Experimental Pharmacologists and Toxicologistss Australia
Connect With Me